Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : to acquire Emisphere Technologies and obtain ownership of the Eligen SNAC oral delivery technology

11/09/2020 | 09:25am EST

Denmark - Novo Nordisk A/S today announced that the company has entered into a definitive agreement to acquire Emisphere Technologies Inc. (Emisphere), a drug delivery company with proprietary technologies, such as the Eligen SNAC technology, that enable oral formulations of therapeutics.

Novo Nordisk and Emisphere have collaborated since 2007 and Emisphere's proprietary drug delivery technology Eligen SNAC is used by Novo Nordisk under an existing licence agreement in the oral formulation of Novo Nordisk's GLP-1 receptor agonist semaglutide, which is marketed and sold under the brand name Rybelsus.

Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Emisphere for USD 1.350 billion. As part of the transaction, Novo Nordisk will also acquire related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC (MHR), the largest shareholder of Emisphere, for USD 450 million. Consequently, the total acquisition price is USD 1.8 billion.

With these acquisitions, Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR and obtains full access to the Eligen SNAC technology platform thereby enabling Novo Nordisk to expand the portfolio of oral biologic pipeline assets across therapy areas.

The transaction will be debt financed and will not impact Novo Nordisk's previously communicated operating profit outlook for 2020 or the ongoing share buyback programme. The acquisition is expected to have a net negative impact on operating profit of less than one percent in 2021 and broadly neutral to positive impact in the following years.

The acquisition of Emisphere provides Novo Nordisk full ownership of the Eligen SNAC technology, which has been successfully used under a licence agreement to develop the first oral biologic, Rybelsus' said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. 'We intend to apply and further develop the technology and use it on current and future pipeline assets with the aim of making more biologic medicines orally available for patients'.

The transaction is subject to customary closing conditions, including approval by Emisphere shareholders and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. MHR and certain other shareholders of Emisphere, collectively owning a majority of the Emisphere shares, have agreed to vote their shares in favour of the transaction.

Novo Nordisk is represented by Davis Polk & Wardwell LLP as legal advisor and Evercore as financial advisor.

About Eligen SNAC Carrier Technology

Eligen SNAC technology enables drug therapies to be provided in a tablet formulation with an absorption-enhancing excipient. Emisphere created Eligen SNAC technology, its proprietary oral drug delivery platform, to facilitate the absorption of small and large molecules without altering their chemical form, biological integrity or pharmacological properties. Notably, the technology enables the transport of therapeutic molecules including large peptides and proteins across biological membranes such as those of the gastrointestinal tract.

About Emisphere

Emisphere is a drug delivery company that utilises its proprietary technologies to develop new oral formulations of therapeutic agents.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries.


Mette Kruse Danielsen

Tel: +45 30 79 38 83

Email: mkd@novonordisk.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
EMISPHERE TECHNOLOGIES, INC. 0.13% 7.81 End-of-day quote.0.00%
NOVO NORDISK A/S 0.08% 443.85 Delayed Quote.3.95%
All news about NOVO NORDISK A/S
01:16aNOVO NORDISK A/S : Files For US Regulatory Approval For Increased Dose Of Type 2..
01/20NOVO NORDISK A/S : Applies for Label Expansion to Introduce New Dosage for Ozemp..
01/20NOVO NORDISK A/S : files for regulatory approval in the US of once-weekly semagl..
01/20NOVO NORDISK : Credit Suisse gives a Neutral rating
01/20NOVO NORDISK : Jefferies remains a Sell rating
01/18NOVO NORDISK : Buy rating from JP Morgan
01/15NOVO NORDISK A/S : Deutsche Bank Initiates Coverage on Novo Nordisk A/S With Buy..
01/15European ADRs Move Sharply Lower in Friday Trading
01/15PRESS RELEASE : BP p.l.c.: BP announces non-executive director resignation
01/15NOVO NORDISK : Buy rating by Deutsche Bank
More news
Sales 2020 127 B 20 768 M 20 768 M
Net income 2020 42 039 M 6 871 M 6 871 M
Net cash 2020 9 590 M 1 568 M 1 568 M
P/E ratio 2020 24,6x
Yield 2020 2,02%
Capitalization 1 026 B 167 B 168 B
EV / Sales 2020 8,00x
EV / Sales 2021 7,63x
Nbr of Employees 44 326
Free-Float 75,1%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 28
Average target price 455,04 DKK
Last Close Price 443,85 DKK
Spread / Highest target 23,9%
Spread / Average Target 2,52%
Spread / Lowest Target -31,3%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S3.95%166 737
JOHNSON & JOHNSON3.18%427 472
ROCHE HOLDING AG3.56%308 129
NOVARTIS AG2.82%219 666
MERCK & CO., INC.0.81%208 627
PFIZER INC.-0.84%202 881